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 2
ABSTRACT 24 
Mutations in the Dihydropteroate synthase (DHPS) gene of Pneumocystis jirovecii 25 
associate with failure of sulfa prophylaxis. They can develop by selection in patients 26 
receiving sulfa drugs, or be acquired via person-to-person transmission. DHPS 27 
mutations raise concern about decreasing efficacy of sulfa drugs, the main available 28 
therapeutic tool for Pneumocystis pneumonia (PCP). The prevalence of Pneumocystis 29 
DHPS mutations was examined in Pneumocystis isolates from 56 sulfa-prophylaxis-30 
naive adults with first-episode of PCP from 2002-2010 in Santiago, Chile. Their clinical 31 
history was reviewed to analyze the effect of these mutations on response to 32 
trimethoprim-sulfamethoxazole (TMP-SMZ) therapy and outcome. Mutant genotypes 33 
occurred in 22(48%) of 46 HIV-infected, and in 5(50%) of 10 HIV-uninfected patients. 34 
Compared to patients with wild type genotype, those with mutant genotypes were more 35 
likely to experience sulfa treatment-limiting adverse reactions, and, to have a twice-36 
longer duration of mechanical ventilation if mechanically ventilated. Specific genotypes 37 
did not associate with death, which occurred in none of the HIV-infected, and in 50% of 38 
non-HIV-infected patients. Chile has a high prevalence of DHPS mutations presumably 39 
acquired through inter-human transmission because patients were not on sulfa 40 
prophylaxis. Results contrast with the low prevalence observed in other Latin American 41 
countries with similar usage of sulfa drugs suggesting additional sources of resistant 42 
genotypes may be possible. The twice-longer duration of mechanical ventilation in 43 
patients with mutant DHPS genotypes may suggest decreased efficacy of TMP-SMZ 44 
and warrant collaborative studies to recognize the relevance of DHPS mutations, and 45 
further research to increase therapeutic options for PCP. 46 
47 
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INTRODUCTION 48 
Pneumonia by the non-culturable opportunistic fungus Pneumocystis jirovecii (PCP), is 49 
a major cause of morbidity and mortality among human immunodeficiency virus (HIV)-50 
infected, and other immunosuppressed patients (1). Pneumocystis, as other fungi, is 51 
unable to scavenge folic acid from the host and needs this gene for synthesis of folate. 52 
Prophylaxis and treatment of this infection relies mostly on the use of the trimethoprim 53 
sulfamethoxazole (TMP-SMZ) combination to inhibit folate synthesis. TMP-SMZ is 54 
widely available and has effectively reduced the incidence of PCP. Sulfa drug usage 55 
however, has been associated with mutations in the active site of the dihydropteroate 56 
synthase (DHPS) enzyme in the fas gene of P. jirovecii which also codes for 57 
dihydroneopterin aldolase and hydroxymethildihydropterin pyrophosphokinase. The 58 
other enzyme involved folic acid synthesis is dihydrofolate reductase (DHFR), which is 59 
coded in a separate gene. The trimethoprim component of TMP-SMZ selectively inhibits 60 
the DHFR enzyme activity, and the sulfamethoxazole component the activity of DHPS in 61 
Pneumocystis and organisms such as Plasmodium falciparum and Streptococcus 62 
pneumoniae, where DHPS and DHFR mutations have been documented as the 63 
mechanism by which sulfa resistance occurs(2-3). Furthermore, most studies have 64 
shown an association between chronic use of sulfa drugs administered as prophylaxis 65 
and presence of DHPS mutations, suggesting drug selection pressure as the 66 
mechanism by which an increase in DHPS mutants in P. jirovecii occur(4-6). It is not 67 
clear whether short term courses of sulfa drug in outpatient settings are sufficient for 68 
selection pressure of DHPS mutants in P. jirovecii. Environments like hospitals or 69 
outpatient clinics are likely more relevant for selection of mutant Pneumocystis as 70 
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patients on chronic sulfa drug use may accumulate mutant genotypes and be a 71 
reservoir for transmission of resistant P. jirovecii strains. This is supported by the high 72 
prevalence of P. jirovecii DHPS mutants in patients with chronic bronchitis that had not 73 
received TMP-SMZ in the previous six months, and by the high transmissibility of 74 
Pneumocystis (7-8).  Germane to this work, mutations in the DHPS gene associate with 75 
decreased sulfa drug efficacy in-vitro and with failure of anti-Pneumocystis 76 
prophylaxis(9-10). Thus, detection of DHPS mutations in P. jirovecii infers that sulfa 77 
resistance might be developing and therefore affecting the efficacy of the first-line agent 78 
used for prophylaxis and treatment of PCP. 79 
The significance of DHPS mutations in clinical response and outcome of PCP treated 80 
with sulfa drugs is still controversial and data on correlation between DHPS mutations 81 
and mortality from PCP is scarce and retrospective studies are conflicting (11-13). It can 82 
be hypothesized however, that the speed of response to sulfa treatment might be 83 
compromised in patients infected by DHPS mutant isolates, delaying clearance of 84 
Pneumocystis and affecting interim outcomes of therapy as for example, the time 85 
connected to mechanical ventilation, oxygen requirements, or others. 86 
DHPS mutant genotypes are selected by sulfa drug selection pressure and have been 87 
used as a marker to infer inter-human transmission of mutant Pneumocystis genotypes 88 
from sulfa-treated patients to individuals non-treated with sulfonamides(14-16). Their 89 
prevalence varies depending on geographical location, suggesting different patterns in 90 
the use of sulfa drugs. Recognition of the incidence of DHPS mutations in a particular 91 
region and whether mutations affect the response to anti-P. jirovecii therapy and 92 
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prophylaxis is therefore warranted. There is a need of more studies to characterize PCP 93 
including the incidence of DHPS mutations of P. jirovecii in Chile (17-19). 94 
In the present study we sought to report the incidence of DHPS mutations among adult 95 
patients without history of prior use of anti-P. jirovecii prophylaxis, and presenting with a 96 
first episode PCP in Santiago, Chile, describing their clinical presentation, response to 97 
therapy, and outcome.  98 
99 
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PATIENTS AND METHODS 100 
Ethics review: The Ethics Committee for Studies in Humans of the University of Chile 101 
School of Medicine approved the study under protocol number 00267. Clinical data was 102 
reported coded to the investigators and analyzed unlinked to the identity of the subjects. 103 
Informed consent for analyses of Pneumocystis isolates was not required. 104 
Patients: Respiratory specimens from adult patients presenting to two hospital clinics in 105 
Santiago, Chile between January 2002 and January 2010 who had not received TMP-106 
SMZ or dapsone (a sulfone) as anti-Pneumocystis prophylaxis and who had first 107 
episode PCP were studied. Their clinical data was collected by means of retrospective 108 
hospital chart review, including patient demographics, past medical history, underlying 109 
cause of immunodeficiency (HIV infection, or other cause), receipt of anti-Pneumocystis 110 
prophylaxis with any agent, other drug treatments, clinical presentation, results of 111 
laboratory tests, and imaging (chest radiography, and computed tomography), clinical 112 
course (including admission to the intensive care unit [ICU] and need for mechanical 113 
ventilation), receipt of adjunctive corticosteroids, response to anti-Pneumocystis 114 
treatment, presence of co-pathogens, and outcome were recorded. Death attributable to 115 
PCP was defined as death caused by progressive respiratory failure. 116 
Sample specimens: Fresh frozen respiratory specimens were sent to the University of 117 
Chile School of Medicine for diagnosis of PCP. They were processed at arrival, and 118 
extracted DNA was kept at -20°C until DHPS genotype analyses. All analyses were 119 
performed “blind” to patients’ clinical details. 120 
Diagnosis of PCP: P. jirovecii organisms were identified using either Grocott Gomori 121 
methenamine silver staining or direct immunofluorescence (MERIFLUOR®, 122 
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Pneumocystis, Meridian, Biosciences). In addition to staining, polymerase chain 123 
reaction (PCR) with standard primers pAZ102-E and pAZ102-H (20) designed to amplify 124 
the gene encoding the mitochondrial large subunit rRNA of Pneumocystis, and which 125 
amplifies all Pneumocystis species, was performed on all specimens prior to 126 
genotyping. 127 
Processing of specimens: Samples were processed inside a biosafety cabinet using 128 
sterile precautions to avoid contamination at all times. They were homogenized with a 129 
sterile pipette and a 200 μL aliquot was used for DNA extraction. DNA was extracted 130 
using the QIAamp DNA Mini kit (Qiagen, Valencia, California) as described (21), and 131 
Platinum® Pfx DNA polymerase (Invitrogen) was used for DNA amplification. Negative 132 
controls were included to monitor for cross-contamination during DNA extraction and 133 
purification steps. An internal control using the human β-globin gene was used in each 134 
sample to detect inhibition of the PCR reaction, i.e., false negative results. Each sample 135 
was run undiluted and as a 1/5 dilution to assess for substrate inhibition. Amplification 136 
products were visualized by ethidium bromide, in 2% agarose gels. 137 
Detection of mutations in the DHPS gene: The DHPS gene binding site was amplified 138 
using single Touch-down PCR using primers DHPS-3: 5’ 139 
GCGCCTACACATATTATGGCCATTTTAAATC 3' and DHPS-4: 140 
5'GGAACTTTCAACTTGGCAACCAC3'  yielding an amplification product of 370 base 141 
pairs as previously described (11, 16, 22). Point mutations in positions 165 (G for T) and 142 
171 (T for C) of the DHPS gene were detected using Restriction Fragment Length 143 
Polymorphism analysis using restriction enzymes AccI (500U 10U/μL, Promega) and 144 
HaeIII (2500U, 10U/ul, Promega). Four DHPS allelic patterns were identified: wild-type 145 
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(genotype 1) and single mutant genotype 2 (point mutation at position 165), single 146 
mutant genotype 3 (point mutation at position 171), and double mutant genotype 4 147 
(point mutations at both position 165 and 171), as previously described (23-24). 148 
Mutations were classified according to the pattern of band polymorphisms visualized on 149 
the 2% agarose gels stained with ethidium bromide. 150 
Statistical analysis: GraphPad Prism 5 software (San Diego, California) was used for 151 
all statistical comparisons. Patient characteristics and clinical outcome were compared 152 
between mutant and wild type groups in HIV-positive patients. Statistical comparisons 153 
were not done in HIV-negative patients because they were too few. Qualitative 154 
characteristics were described using absolute frequency, and percentages and 155 
intergroup comparisons among mutant and wild type groups were performed using 156 
Fisher’s exact test. Non-normally distributed quantitative variables were described using 157 
medians and interquartile ranges (IQR) and comparisons were made using Mann 158 
Whitney Test. Normally distributed quatitative data were described using means and 159 
standard deviations (SD), and comparisons were made using the unpaired t-test. A p 160 
value of <0.05 was considered significant.  Proportions of DHPS mutants overtime were 161 
compared using χ2. All comparisons were two-tailed and confidence level was set at 162 
95%.  163 
164 
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RESULTS 165 
Patients and sample characteristics 166 
A total of 56 respiratory specimens corresponding to 56 adult patients with available 167 
medical history and who had not received TMP-SMZ or dapsone as Pneumocystis 168 
prophylaxis and presented with a first episode of PCP were found in our respiratory 169 
specimens collection. All were immunosuppressed: 46(82%) were HIV-infected, and 170 
10(18%) had other causes of immunosuppression: HTLV-1 associated T-cell lymphoma 171 
(n=1), meningioma (n=1), rheumatoid arthritis (n=1), dermatomyositis (n=1), psoriatic 172 
arthritis (n=1), systemic lupus erythematosus (n=1), Churg-Strauss syndrome (n=1), 173 
myasthenia gravis (n=1), chronic obstructive pulmonary disease (n=1), and chronic 174 
renal failure (n=1). The median age for HIV-infected patients was 38.5 years (range 22 - 175 
71), and for non-HIV infected was 56.5 years (range 18 - 82). Forty five (98%) of the 46 176 
HIV-infected patients and four (40%) of the 10 non-HIV infected patients were male. 177 
PCP was the AIDS-defining condition in 36 (78%) of the HIV-infected patients. Only one 178 
of the eight patients with HIV infection diagnosed prior to their PCP episode was 179 
receiving antiretroviral therapy. Median CD4+ T-cell count among HIV infected patients 180 
was <40 cells/µl (Table 1).  181 
Five specimens were obtained during the period 2002 - 2004, 16 during 2005 - 2007; 182 
and 35 in 2008 - 2010. They consisted of bronchoalveolar lavage (BAL) fluid (n=26), 183 
tracheal aspirate (n=16), spontaneously expectorated sputum (n=13), and 184 
nasopharyngeal aspirate (n=1).  185 
Parameters to characterize the degree of severity of PCP were not standardized, and 186 
individual patients' receipt of supplemental oxygen, and their arterial oxygen tension or 187 
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 10
saturation measurements (obtained while breathing room air) were not recorded 188 
systematically. However, all patients were admitted to the hospital, and the majority 189 
54(96%) required supplemental oxygen. No significant differences were detected in 190 
clinical parameters at admission (fever, cough, dyspnea, chest radiography, computed 191 
tomography, platelet count, serum albumin, lactate dehydrogenase and C-reactive 192 
protein levels) among HIV-infected and non-infected patients.  193 
Previous use of trimethoprim-sulfamethoxazole 194 
Hospital medical records were reviewed for use of TMP-SMZ. This sulfa-drug 195 
combination is available in the Chilean therapeutic armamentarium, and occasionally 196 
prescribed for respiratory and urologic conditions. Except for two patients with asthma 197 
whose P. jirovecii isolates were DHPS genotype 1 (wild-type), only one other patient 198 
had chronic lung disease. None of the patients had urologic conditions referred in the 199 
medical history at hospital admission. No use of TMP-SMZ as inpatients was 200 
documented. Outpatient and primary care medical records were not accessible. 201 
Prevalence of DHPS mutations 202 
Mutations in the DHPS gene were identified in 27 (48%) of 56 patients regardless of 203 
their underlying diagnosis (Table 2). Mutations occurred in one (20%) of the five isolates 204 
collected between 2002 - 2004, five (31%) of the 16 isolates collected between 2005-205 
2007, and 21 (60%) of the 35 isolates collected between 2008-2010 (p = 0.06). 206 
Polymorphisms consisting of DHPS genotypes 2, 3, or 4 were present in 22 (48%) of 207 
the 46 HIV-infected and in five (50%) of the 10 non-HIV infected patients with PCP. Co-208 
infections with wild type genotype were more frequent in the HIV-infected group, and 209 
were absent in non-HIV infected patients with PCP (Table 2). No predominant pattern of 210 
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mutation polymorphism was detected. We  analyzed co-infections by grouping co-211 
infections during 2002 - 2008, the first 6 years (n =13), and those during the last 3 years 212 
2009 - 2012 (n = 9) of the study. Eight (61%) of 13 co-infections during the first time 213 
period compare to seven (77%) of nine co-infections in the second period (p = 0.42). 214 
 215 
Clinical parameters and outcome 216 
Anti-PCP treatment was initiated with TMP-SMZ in 53 (95%) of the 56 patients. TMP-217 
SMZ combined with caspofungin or dapsone was used in two patients, and 218 
pyrimethamine-sulphadoxine in one patient. Among HIV-infected patients, 219 
discontinuation of TMP-SMZ, related to sulfa-related adverse events and not to 220 
treatment failure, was needed in four (18%) of 22 patients with mutant genotypes and in 221 
none of 24 with wild type isolates (p =0.045). Among HIV-infected patients requiring 222 
mechanical ventilation, the duration of mechanical ventilation among those harboring 223 
DHPS mutations was significantly longer, 11 days (IQR 8-56), than in those with wild 224 
type isolates, 6 days (IQR 2-8); p =0.017. There was a trend towards longer 225 
hospitalization in HIV-infected patients with mutations, 20 days (IQR 10-42), compared 226 
with 11 days (IQR 6 - 19) in those HIV-infected patients with wild type DHPS isolates; p 227 
=0.073, (Table 3). All 46 (100%) HIV infected patients survived whereas only five (50%) 228 
of the ten non-HIV infected patients survived. Death was directly attributable to PCP in 229 
three of them.   230 
231 
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DISCUSSION 232 
Nearly half of the patients in this study, regardless of their HIV-status, had 233 
Pneumocystis DHPS mutant genotypes despite no prior receipt of sulfa drugs 234 
(sulfamethoxazole or dapsone) as prophylaxis of PCP, therefore suggesting that 235 
human-to human transmission was the most likely source of acquisition of mutant 236 
isolates. Our results also, showed that mechanically ventilated patients harboring 237 
Pneumocystis DHPS mutant genotypes had a twice-longer duration of mechanical 238 
ventilation suggesting that these mutations might have impacted the response to anti-239 
Pneumocystis treatment with sulfamethoxazole-containing sulfa combinations. In 240 
addition, adverse drug reactions to sulfa treatment of PCP, necessitating treatment 241 
change, were observed more frequently among those with mutant DHPS genotypes. 242 
A high prevalence of DHPS mutations has also been reported in studies from other 243 
countries. For example, a recent study of AIDS related PCP in Kampala, Uganda 244 
documented that all 13 isolates of P. jirovecii harbored either single or double mutant 245 
DHPS genotypes, despite only two persons were receiving TMP-SMZ for PCP 246 
prophylaxis (25). This finding was ascribed to population-level selection pressure due to 247 
sulfa drug use for treatment of malaria caused by Plasmodium falciparum among the 248 
general population. Pneumocystis is not zoonotic, therefore the absence of sulfa 249 
prophylaxis for PCP in our patients suggests that they likely acquired DHPS mutations 250 
through inter-human transmission (14, 16). The mechanism and role for selection 251 
pressure at a population level is, however, not clear because sulfa drugs are the third or 252 
fourth choice of antibiotic for treatment of respiratory and urinary tract infections, in both 253 
primary and secondary care settings in Chile. They account for approximately 5% of 254 
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antibiotic prescriptions after synthetic penicillins, macrolides, cephalosporins, and 255 
quinolones (26). Furthermore, the use of the TMP-SMZ combination has decreased 256 
since 2000 from approximately 7% to 2% of total antibiotic consumption in Chile(26). 257 
This consumption is similar to that reported in other Latin American countries (27) 258 
where low usage of sulfa drugs parallels a low prevalence of DHPS mutations.  Of note, 259 
an earlier UK study showed a 36% frequency of DHPS mutations in isolates of P. 260 
jirovecii in London, when there was population-level "selection pressure" from 261 
widespread use of sulfa drugs both as prophylaxis against PCP, and among the general 262 
population for treatment of respiratory and urinary tract infections (28). 263 
Contemporaneously, a low prevalence (7.7%) of DHPS mutants were identified in 264 
Zimbabwe, where sulfa drugs were rarely used. When in UK selection pressure was 265 
removed a predominance (80%) of wild type genotypes was observed (28). Restriction 266 
measures for use of antibiotics have been in place in Chile since 1998, however, there 267 
is no indication that the frequency of detection of DHPS mutants has decreased. By 268 
contrast, the possible increase in proportion of DHPS mutations overtime suggested in 269 
this study becomes paradoxical when the parallel decrease in use of sulfa drugs by 270 
national policies is considered. Therefore, the high frequency described in this study 271 
seems too high to be explained solely by sulfa selection pressure within human 272 
population. 273 
Restriction of antibiotics in humans in Chile has not been accompanied by similar 274 
policies in veterinary settings, and currently there is a far greater use of antibiotics 275 
including sulfa drugs in the setting of pig, poultry, and fish farming than in humans in 276 
Chile (29). Veterinary use of sulfa drugs may select DHPS mutants on a much larger 277 
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scale than in human use, and acquisition of bacterial genes generally responsible for 278 
metabolic or virulence traits via horizontal gene transfer (HGT) has been documented in 279 
fungal species(30-31). However, this type of acquisition of resistance has never been 280 
described in Pneumocystis. Mutations in the DHPS gene of P. jirovecii have been 281 
shown to arise independently among multiple Pneumocystis strains (32). Therefore, 282 
transmission of a single resistant clone of  P. jirovecii appears to be very unlikely. 283 
The finding that adverse drug reactions to sulfa treatment were more frequent among 284 
patients with mutant DHPS genotypes, whom in turn required more frequent changes in 285 
anti-PCP treatment, does not have an immediately apparent explanation. Short courses 286 
of sulfa drugs, for example as treatment for bronchitis or sinusitis could not be identified 287 
from hospital records, and therefore, the possibility of prior exposure in a primary care 288 
setting resulting in sensitization cannot be excluded. However, the two patients with 289 
asthma, and one additional patient with chronic obstructive lung disease, in whom the 290 
possibility of them having received undocumented sulfa-containing antibiotics in a 291 
primary care was more likely, had wild type DHPS genotype 1.  292 
No difference in the proportion of patients with wild type and mutant genotypes requiring 293 
mechanical ventilation was detected in the present study. This observation contrasts 294 
with a study by Crothers et al, where 14.3% of patients with PCP and mutant P. jirovecii 295 
genotypes required mechanical ventilation, compared with 2.5% of those with wild type 296 
P. jirovecii genotypes (p = 0.056) (33). However, mutant DHPS genotypes were 297 
associated with a longer duration of mechanical ventilation in the present series and this 298 
data suggests further research is needed (by way of a multi-center prospective study), 299 
as data from the present study infer a reduced ability of sulfa-based regimens to clear 300 
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 15
DHPS-mutant P. jirovecii from the lungs. Interestingly, the study by Crothers et al also 301 
showed patients with mutant DHPS genotypes had a non-significant trend to longer 302 
overall hospital stay, but data on duration of mechanical ventilation is not provided (33). 303 
The inability to culture Pneumocystis in-vitro hinders antimicrobial sensitivity testing and 304 
makes proof of a mechanistic connection difficult. Moukhlis et. al. performed functional 305 
studies using a DHPS-deficient model of Sacharomyces cerevisiae experimentally 306 
complemented with Pneumocystis mutant and wild type DHPS, and documented a 307 
decreased susceptibility to sulfamethoxazole in those S. cerevisiae isolates that were 308 
complemented with double mutant genotypes(34). Their results, and related earlier work 309 
provide an in-vitro correlation with our findings(9-10, 34).   310 
In the present study, we observed no association between mutant DHPS-genotype and 311 
mortality. However this was an observational study and so was not powered to show 312 
differences. Of interest, a prospective single cohort study from San Francisco General 313 
Hospital consisting of 301 patients with laboratory-confirmed PCP, over a period of >10 314 
years, demonstrated that although receipt of recent sulfa prophylaxis was associated 315 
with mutant genotypes of P. jirovecii, detection of mutant DHPS genotypes was not 316 
associated with mortality. This observation conflicts with findings from other authors (13, 317 
35).  318 
The strengths of the present study are that it is the first from Chile to describe DHPS 319 
genotyping among P. jirovecii isolates from patients with PCP. Our results document a 320 
high frequency of DHPS mutants (48%) in anti-P. jirovecii sulfa-prophylaxis-naive 321 
patients with a first episode of PCP. This frequency is excessively high when compared 322 
to the low prevalence of DHPS mutations in countries in the same continent, for 323 
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example Brazil (0%) and Colombia (6.6%) that report similar patterns of sulfa-drug 324 
usage in humans(27, 36-37). Therefore, although our findings add further evidence to 325 
support the hypothesis of inter-human transmission as a mechanism of acquisition of 326 
mutant P. jirovecii types, additional mechanisms of acquisition may be possible. 327 
Significantly, our results also suggest that DHPS mutation can diminish the efficacy of 328 
sulfa-drug treatment of PCP by documenting a significantly longer duration of 329 
mechanical ventilation in patients harboring mutant DHPS genotypes, and highlight the 330 
need to increase the anti-Pneumocystis armamentarium. TMP-SMZ is the only anti-331 
Pneumocystis drug available in most of the world. Weaknesses of the present study are 332 
the lack of prospective, systematic acquisition of clinical data, and the relatively small 333 
sample size.  334 
In conclusion, we describe a high frequency of DHPS mutations among adult patients 335 
with first-episode of PCP who had not received sulfa drugs as PCP prophylaxis in 336 
Santiago, Chile. The likely explanation being inter-human transmission and selection 337 
pressure from sulfa drugs prescribed for other conditions. Additionally, the potential role 338 
of veterinary use of sulfa drugs in selection of DHPS mutations for transmission to 339 
humans deserves further study. Patients with PCP and mutant DHPS genotypes were 340 
more likely to experience treatment-limiting adverse reactions to sulfa-drug treatment, 341 
and to require a longer duration of mechanical ventilation, thus inferring a decrease on 342 
treatment efficacy. The final treatment outcome was not affected, as patients harboring 343 
mutant DHPS genotypes were no more likely to die. The prevalence of DHPS mutations 344 
in clinical isolates of Pneumocystis should be monitored, and their significance in 345 
delaying response to therapy needs to be confirmed in larger collaborative studies.  346 
347 
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   Table 1. Demographic and clinical characteristics of 56 patients with first episode of Pneumocystis pneumonia (PCP). 
 
 HIV-infected n=46 Non-HIV-infected n=10 
 n/n total (%)  n/n total (%)  
 Wild-type DHPS 
genotypes 
24/46 (52)
Mutant DHPS 
genotypes 
22/46 (48)
 
p value 
Wild-type DHPS 
genotypes 
5/10 (50)
Mutant DHPS 
 genotypes 
5/10 (50)
 
p value 
Mean age [years] (SD) 40 (12.2) 40.1 (9.3) 0.977 48.5 (24.7) 55.6 (23.3) 0.671 
Male gender  24/24 (100) 21/22 (95) 0.468  2/5 (40) 2/5 (40) 1  
New HIV diagnosis 20/24 (83) 18/22 (82) 0.699 NA NA
Receipt of PCP prophylaxis  0/24 (0) 0/22 (0) 1 0/5 0/5 NA 
Not receiving antiretroviral Therapy  24/24 (100) 21/22 (96) 0.478 NA NA  
Fever  
    Mean temperature [ºC] (SD) 
15/24 (63) 
38.1 (0.85)
12/22 (55) 
38.2 (0.98)
0.765  
0.786
3/5 (60) 2/3 (67) 1  
Cough   18/24 (75) 19/22 (86) 0.464   3/5 (60) 3/4 (75) 1  
Dyspnoea  21/24 (88) 19/21 (91) 1  4/5 (80) 3/4 (75) 1  
Chest radiograph  22/24 21/22 5/5 5/5
  Abnormal 21/22 (96) 21/21 (100) 1 5/5 (100)  5/5 (100)
  Bilateral interstitial infiltrates  18/22 (82) 16/21 (76)  1/5 (20) 1/5 (20) NA 
  Another pattern  
  Not determined 
3/22 (14)a 5/21 (24)b   2/5 (40)c
2/5 (40)
 4/5 (80)d  
Thoracic CT scan  15/25 15/22 3/5 3/5
   Abnormal 15/15 (100) 15/15 (100) 1 3/3 (100) 3/3 (100) NA
      Ground glass infiltrates 12/15 (80) 14/15 (93)  1/3 (33) 1/3 (33)  
      Another pattern 3/15 (20)e 1/15 (7)f 2/3 (67)g 2/3 (67)h 
Median CD4 cell count [cell/μl] (IQR) 
 n 
27 (11–57.5) 
(20/24)
37 (18-64) 
(19/22)
0.465 ND ND  
Median serum albumin [g/l] (IQR) 
 n 
2.95 (2.37-3.40) 
(18/24)
2.90 (2.40-3.30) 
(13/22)
0.794 3.15 (2.35-3.43) 
(4/5)
ND  
Median serum LDH [IU/l] (IQR) 
 n 
854.5 (568.8-1290) 
(22/24)
863 (665-1089) 
n=19
0.927 875 (558,8-3210) 
(4/5)
1099 (840-1405) 
(5/5)
0.730 
Mean haematocrit [%] (SD)] 
 n 
39.9 (6.39) 
(23/24)
36.8 (4.72) 
(21/22)
0.076 30.1 (8.84) 
(5/5)
31.5 (9.54) 
(4/5)
0.782 
Median C-reactive Protein [mg/l] (IQR) 
 n 
19.6 (4.8-99.9) 
(18/24)
8.5 (1.1-86.2) 
(19/22)
0.475 73 (3.40-217.0) 
(5/5)
5,0 (1.90-50.25) 
(4/5)
0.191 
Other lung pathology 2/24(8)i 1/22 (5)j 1 3/5(60)k 1/5 (20)l 0.524 
Key: DHPS = dyhydropteroate synthase; LDH = Lactate dehydrogenase. NA = not applicable; ND = not determined 
a Bilateral interstitial infiltrates plus bilateral lobar consolidation =1; bilateral interstitial infiltrates plus bilateral alveolar consolidation =1;  diffuse basal infiltrates =1 
b Bilateral interstitial infiltrates plus air bronchogram and consolidation  =1; diffuse alveolar- interstitial pattern =2; diffuse alveolar- interstitial pattern with apical cavitation =1; right lobar 
consolidation =1 
c Alveolar haemorrhage =1; left pulmonary nodules =1 
d Bilateral peri-bronchovascular thickening =1; Right basal consolidation =1; bilateral alveolar consolidation plus air bronchogram =1; right middle lobe consolidation =1 
e Bilateral ground- glass infiltrates and bilateral consolidation =1; non- characteristic interstitial infiltrates =1; diffuse infiltrates =1 
f  Bilateral ground-glass infiltrates and four cavitation- suggestive nodules (1) 
gAlveolar Hemorrhage (1); pneumomediastinum (1) 
h Bilateral ground glass pattern and unilateral consolidation (1); unilateral consolidation (1)  
i Bronchial asthma (2) 
j Mycobacterium tuberculosis 
k Dermatomyositis (1); COPD plus Cystic fibrosis (1); Bronchial asthma (1) 
l Myasthenia gravis    489 
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Table 2: Pneumocystis jirovecii Dihydropteroate Synthase genotypes in respiratory specimens from 56 adult patients with newly diagnosed 490 
Pneumocystis pneumonia. 491 
  
DHPS genotype* HIV-infected (n = 46) [n positive/n total (%)] 
Non-HIV-infected (n = 10) 
[n positive/n total (%)] 
Wild-type  
G1 
 
 
24/46 (52) 
 
5/10 (50) 
Mutant  
 
Single mutant 
  G2 (position 165) 
G3 (position 171) 
 
Double mutant 
G4 (position 165 + 171) 
 
Co-infection with wild-type 
 G5 (1 + 2)  
 G6 (1 + 3) 
 G7 (1 + 4) 
 
Mixed single + double mutant 
 G8 (2 + 4) 
22/46 (48) 
 
2/22 (9) 
1/22 (5) 
1/22 (5) 
 
 
5/22 (23) 
 
15/22 (68) 
9/22 (41) 
0 
6/22 (27) 
 
 
0 
5/10 (50) 
 
2/5 (40) 
2/5 (40) 
0 
 
 
3/5 (60) 
 
0 
0 
0 
0 
 
 
0 
 
*Genotypes (G1 - G8) as described in ref. 24. 492 
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 Table 3:  Dihydropteroate Synthase genotypes and clinical outcomes among 56 patients with first episode of Pneumocystis pneumonia. 
 HIV-infected
n=46 
Non-HIV-infected
n=10 
 Treatment and outcome  
 [n (%)] 
Wild-type DHPS 
genotypes 
(n=24) 
Mutant DHPS 
genotypes 
(n=22) 
p value 
Wild-type DHPS
genotypes 
(n=5) 
Mutant DHPS
 genotypes 
(n=5) 
p value 
Initial treatment with trimethoprim-
sulfamethoxazole  23 (96)i 20 (91)ii 0.600 5 (100) 5 (100) ND 
Adverse effect  2 (8)iii 4 (18) iv 0.452 0 (0) 0 (0) ND 
Need for treatment change  0 (0) 4 (18)v 0.045 1 (17)vi 0 (0) ND 
Sulfa allergies  1 (4) 4 (18) 0.178 0 (0) 0 (0) ND 
Adjunctive corticosteroids  21 (84) 15 (70) 0.159 4 (83) 4 (80) ND 
Duration of hospitalization, days 
 Median (IQR)  
 n with available data / n  
 
11 (6-19) 
19/24 
 
20 (10-42) 
16/22 
 
0.073 
 
30 (14-40) 
5 
 
25 (8-37) 
5 
 
ND 
Required supplemental Oxygen  
 Median (days [IQR]) 
 n with available data / n 
24 (100) 
11.5 (6.7-19.5) 
22/24 
20 (91) 
14.5 (7.0-20) 
20/22 
 
0.203 
 
5 (100) 
34 (14-40) 
5 
5 (100) 
17 (10-24) 
5 
 
ND 
Need for early ICU admission  
 n with available data / n 
8 (36) 
22/24 
7 (35) 
20/22 
0.763 1 (20) 
5 
3/4 (75) 
4 
ND 
Mechanical ventilation  9 (38) 7 (32)  4 (80) 5(100)  
 Median (days [IQR]) 6 (2.25-7.75) 11 (8-56) 0.017 25 (10-30) 14 (8-35) ND 
Pulmonary co-infection  
 Bacterial 
 Viral 
 Bacterial + Viral 
7 (29) 
1i 
4j 
2k 
5 (23) 
3l 
0 
2m 
 
3 (60) 
3n 
0 
0 
2 (40) 
2 o 
0 
0 
 
Treatment outcome    
 Survived 
 Died  
 Death due to PCP 
 
24 (100) 
0 (0) 
0 (0) 
 
22 (100) 
0 (0) 
0 (0) 
  
2 (40) 
3 (60)  
2 (40) 
 
3 (60) 
2 (40)  
1 (20) 
 
(i) pyrimethamine + sulfadoxine (1) 
(ii) caspofungin + trimethoprim-sulfamethoxazole (TMS) (1), dapsone +TMS (1) 
(iii) rash (2) 
(iv) rash (2), acute kidney injury (1), rash, interstitial nephritis, hepatitis (1) 
(v) change TMS to: dapsone (2), dapsone + clindamycin (1) 
(vi)treatment failure change to iv pentamidine 
 
IAcinetobacter baumannii =1, 
jCytomegalovirus (CMV) 
kAcinetobacter baumannii + CMV =1, Enterobacter cloacae + CMV =1 
lStreptococcus pneumoniae =1, Klebsiella pneumoniae =2, Stenotrophomonas maltophilia 
=1 
mβ-haemolytic Streptococcus + CMV =1, atypical Mycobacteria + CMV =1 
nPseudomonas aeruginosa =1, Klebsiella pneumoniae =1, Proteus mirallis =1 
0Enterobacter cloacae =2 
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